Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy

Journal of Urology

Volumn 184, Issue 3, 2010, Pages 907-912

  Vickers, Andrew J ^a   Wolters, Tineke ^d   Savage, Caroline J ^a   Cronin, Angel M ^a   O'Brien, M Frank ^a   Roobol, Monique J ^d   Aus, Gunnar ^b   Scardino, Peter T ^a   Hugosson, Jonas ^b   Schrder, Fritz H ^d   Lilja, Hans ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

biopsy; diagnosis; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REPEAT PROCEDURE; BIOPSY; BLOOD; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; STATISTICS; TIME;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 77956630147     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.05.029     Document Type: Article

References (25)

1. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035
2. Z.A. Dotan, F.J. Bianco Jr, and F. Rabbani Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy J Clin Oncol 23 2005 1962
3. D. Robinson, G. Sandblom, and R. Johansson PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer Urology 72 2008 903
4. S. Sengupta, R.P. Myers, and J.M. Slezak Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy J Urol 174 2005 2191
5. S. Loeb, K.A. Roehl, and W.J. Catalona Prostate specific antigen velocity threshold for predicting prostate cancer in young men J Urol 177 2007 899
6. H.B. Carter, J.D. Pearson, and E.J. Metter Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 1992 2215
7. National Comprehensive Cancer Network Prostate Cancer Detection, version 2.2010 www.nccn.org Accessed June 1, 2010
8. A.J. Vickers, C. Savage, and M.F. O'Brien Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398
9. A.J. Vickers, T. Wolters, and C.J. Savage Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Eur Urol 2009 Epub ahead of print
10. S.E. Eggener, K.A. Roehl, and W.J. Catalona Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy J Urol 174 2005 500
11. A. Rodriguez Alonso, A. Gonzalez Blanco, and A. Barbagelata Lopez Importance of PSA velocity and PSA density in the prediction of prostate cancer in TURP or open prostatectomy specimen of patients with previous negative prostate biopsy Actas Urol Esp 32 2008 779
12. J. Hugosson, G. Aus, and H. Lilja Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma Cancer 100 2004 1397
13. A.J. Vickers, A.M. Cronin, and G. Aus A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden BMC Med 6 2008 19
14. M.J. Roobol, W.J. Kirkels, and F.H. Schroder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) BJU Int 92 suppl. 2003 48
15. A.V. D'Amico, A.A. Renshaw, and B. Sussman Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy JAMA 294 2005 440
16. R. Raaijmakers, M.F. Wildhagen, and K. Ito Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam Urology 63 2004 316
17. M.J. Roobol, R. Kranse, and H.J. de Koning Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam) Urology 63 2004 309
18. T. Wolters, M.J. Roobol, and C.H. Bangma Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam) Eur Urol 55 2009 385
19. N. Bittner, G.S. Merrick, and H. Andreini Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB Urology 74 2009 171
20. L. Benecchi, A.M. Pieri, and M. Melissari A novel nomogram to predict the probability of prostate cancer on repeat biopsy J Urol 180 2008 146
21. I.M. Thompson, C.M. Tangen, and D.P. Ankerst The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy J Urol 180 2008 544
22. P.H. Gann, A. Fought, and R. Deaton Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach J Clin Oncol 28 2010 1714
23. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529
24. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591
25. D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835